MIRUM PHARMACEUTICALS INC

Mirum Pharma’s insider trades, strong Phase IIb results, and new regulatory approvals signal confidence in its MIR‑202 therapy for cholestatic liver disease.

Mirum insider selling trend shows CFO Eric Bjerkholt liquidating shares while retaining long‑term stake—investors should watch for impact on stock price.

CEO Peetz’s July 6 insider trades on Mirum Pharma—small option‑exercise buy and balanced sales—show no market impact, offering investors a clear view of routine liquidity management.

Mirum Pharmaceuticals insider sale shows routine portfolio management, not a warning—strong pipeline growth, solid insider confidence, and SEC‑compliant trading.

Mirum Pharmaceuticals insider sale: a routine liquidity move, not a warning, with shares up 7.46 % week‑to‑week and a strong oncology pipeline gaining breakthrough status. Read how it impacts investors and patients.

Mirum Pharmaceuticals’ CFO trades reveal disciplined equity strategy while its fast‑track cholestatic liver therapy, Mirum‑L, heads toward a pivotal Phase III study—an insider‑led move poised to boost investor confidence.

Insightful insider buying by Mirum Pharmaceuticals’ director hints at a soon‑to‑come milestone in its cholestatic liver‑disease pipeline, boosting investor confidence amid strong market fundamentals and favorable regulatory trends.

Mirum Pharmaceuticals’ director buys 2,000 shares at $23.51, signaling insider confidence amid volatile pricing and a focus on liver‑disease therapeutics.

Insider buying at Mirum Pharmaceuticals signals confidence in its liver‑therapy pipeline; CFO’s recent trades hint at future upside.

Mirum Pharmaceuticals insider trades reveal CMO’s confidence in Phase III liver‑disease therapy, blending stock purchases with tax‑smart PRU sales for strategic gains.